The molecular genetic landscape of human brain size variation.
CP: Neuroscience
TWAS
brain development
imaging genetics
psychiatric disorders
transcriptomics
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
09
11
2022
revised:
13
06
2023
accepted:
27
10
2023
medline:
4
12
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
ppublish
Résumé
Human brain size changes dynamically through early development, peaks in adolescence, and varies up to 2-fold among adults. However, the molecular genetic underpinnings of interindividual variation in brain size remain unknown. Here, we leveraged postmortem brain RNA sequencing and measurements of brain weight (BW) in 2,531 individuals across three independent datasets to identify 928 genome-wide significant associations with BW. Genes associated with higher or lower BW showed distinct neurodevelopmental trajectories and spatial patterns that mapped onto functional and cellular axes of brain organization. Expression of BW genes was predictive of interspecies differences in brain size, and bioinformatic annotation revealed enrichment for neurogenesis and cell-cell communication. Genome-wide, transcriptome-wide, and phenome-wide association analyses linked BW gene sets to neuroimaging measurements of brain size and brain-related clinical traits. Cumulatively, these results represent a major step toward delineating the molecular pathways underlying human brain size variation in health and disease.
Identifiants
pubmed: 37963017
pii: S2211-1247(23)01451-1
doi: 10.1016/j.celrep.2023.113439
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113439Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.S., R.A.I.B., J.D.B., and A.F.A.-B. are directors and hold equity in Centile Bioscience. J.D.B. holds positions/equity in UpFront Diagnostics, Treovir, and NeuroX1. A.F.A.-B. receives consulting income from Octave Bioscience.